Novavax announces high efficacy in phase 3 trials

American biotech company Novavax announced yesterday that their COVID-19 vaccine PREVENT-19 demonstrated 90% overall efficacy in its phase 3 trial, and provides 100% protection against moderate and severe disease.

The phase 3 trial showed PREVENT-19 had high efficacy (90.3%) against newer variants of concern and variants of interest (VOC and VOI respectively). This means that PREVENT-19 may be particularly useful in the ongoing fight against rapidly mutating variants, like those that have emerged in South Africa (Beta variant), the UK (Alpha) and India (Delta).

Full article at: